PWMG
CYTK icon

Prestige Wealth Management Group’s Cytokinetics CYTK Stock Holding History

Prestige Wealth Management Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$767 Hold
9
– – ﹤0.01% 966
2026
Q1 		$594 Hold
9
– – ﹤0.01% 942
2025
Q4 		$572 Hold
9
– – ﹤0.01% 928
2025
Q3 		$495 Hold
9
– – ﹤0.01% 932
2025
Q2 		$298 Hold
9
– – ﹤0.01% 972
2025
Q1 		$362 Hold
9
– – ﹤0.01% 963
2024
Q4 		$424 Hold
9
– – ﹤0.01% 985
2024
Q3 		$476 Hold
9
– – ﹤0.01% 973
2024
Q2 		$488 Hold
9
– – ﹤0.01% 925
2024
Q1 		$631 Hold
9
– – ﹤0.01% 932
2023
Q4 		$752 Hold
9
– – ﹤0.01% 888
2023
Q3 		$266 Buy
+9
New +$300 ﹤0.01% 1018

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prestige Wealth Management Group's CYTK Position: Q2 2026 in Review

Prestige Wealth Management Group held its Cytokinetics (CYTK) position steady in Q2 2026 at 9 shares worth $767. The position accounts for ﹤0.01% of the portfolio, ranked #966.

Prestige Wealth Management Group first reported a position in CYTK in Q3 2023 and has held it in 12 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Prestige Wealth Management Group held 9 shares of Cytokinetics worth $767 as of Q2 2026.
  • Prestige Wealth Management Group left its Cytokinetics share count unchanged in Q2 2026.
  • Cytokinetics made up ﹤0.01% of Prestige Wealth Management Group's portfolio in Q2 2026, its #966 holding.
  • Prestige Wealth Management Group first reported a position in Cytokinetics in Q3 2023 and has held it in 12 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Prestige Wealth Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.